India's Wockhardt up on plans to shut down loss-making US business
** Shares of Wockhardt WCKH.NS rise 4.4% to 1,829.5 rupees, their highest in over 3 weeks ** Pharma co plans to shut down its loss-making US generic pharmaceutical segment in 15 months ** The shutdown is part of its US ops' realignment to focus on two segments - new antibiotic drug discovery, and biologicals portfolio in insulin ** Stock up 27.6% YTD (Reporting by Aleef Jahan in Bengaluru) ((aleefjahan.cs@thomsonreuters.com))
Recent news on Wockhardt
See all newsBrief: Wockhardt Says Customs Authority Imposes 50 Million Rupees Penalty And 100 Million Rupees Redemption Fine On Co
Brief: Wockhardt Limited June-Quarter Consol Net Profit 1.06 Billion Rupees
India's Wockhardt gains after marketing authorization for antibiotic ZAYNICH
Brief: Wockhardt Says Indian Drug Regulator Grants Marketing Authorization To Co's Zaynich
India's Wockhardt hits 7‑month high after swinging to profit in fourth quarter